BMS-F is a chemical from the aminoalkylindole family invented by Bristol-Myers Squibb around 1999, that acts as a potent and selective agonist for the cannabinoid receptor CB2, with a Ki of 8 nM at CB2 and 500x selectivity over the related CB1 receptor. It has antiinflammatory effects and inhibits release of TNF-α.
See also A-796,260 APP-FUBINACA JWH-200 MDMB-FUBINACA MN-25 Pravadoline S-777,469 WIN 55,212-2
References